scispace - formally typeset
Open AccessJournal ArticleDOI

The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology.

Reads0
Chats0
TLDR
Improved definitions of TCMR and ABMR in pancreas transplants with specification of vascular lesions and prospects for defining a vascularized composite allograft rejection classification are included.
About
This article is published in American Journal of Transplantation.The article was published on 2017-01-01 and is currently open access. It has received 522 citations till now. The article focuses on the topics: Transplantation.

read more

Citations
More filters
Journal ArticleDOI

The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection

TL;DR: This report on kidney transplant pathology details clarifications and refinements to the criteria for chronic active (CA) T cell–mediated rejection, borderline, and antibody‐mediated rejection (ABMR).
References
More filters
Journal ArticleDOI

Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.

TL;DR: This prospective cohort indicates that many actual failures after indication biopsies manifest phenotypic features of antibody‐mediated or mixed rejection and also underscores the major role of nonadherence.
Journal ArticleDOI

Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups

TL;DR: The willingness of the Banff process to adapt continuously in response to new research and improve potential weaknesses, led to the implementation of six working groups on the following areas: isolated v‐lesion, fibrosis scoring, glomerular lesions, molecular pathology, polyomavirus nephropathy and quality assurance.
Journal ArticleDOI

Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.

TL;DR: A non-HLA, AT1-receptor-mediated pathway may contribute to refractory vascular rejection, and affected patients might benefit from removal of At1- receptor antibodies or from pharmacologic blockade of AT1 receptors.
Related Papers (5)